Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus

Lupus

Volumn 14, Issue 7, 2005, Pages 505-509

  López Hoyos, Marcos ^a   Cabeza, R ^a   Martinez Taboada V M ^a   Crespo, J ^a   SanSegundo, D ^a   Blanco, R ^a   Lopez Escribano H ^a   Pena M ^a   Rodriguez Valverde V ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anti dsDNA antibodies; Immunofluorescence; Nephritis; SLEDAI

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA ANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CRITHIDIA LUCILIAE FLUORESCENCE TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DISEASE ACTIVITY; DISEASE MARKER; FARR TEST; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; COHORT STUDIES; COMPLEMENT C3; COMPLEMENT C4; DNA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 23844550571     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2130oa     Document Type: Article

References (17)

1. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
2. Isenberg D, Smeenk R. Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus 2002; 11: 797-800.
3. Brinkman K, Termaat R, van den Brink H, Berden J, Smeenk R. The specificity of the anti-dsDNA ELISA. A closer look. J Immunol Methods 1991; 139: 91-100.
4. Hernando M, Gonzalez C, Sanchez A et al. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay. Clin Chem Lab Med 2002; 40: 1056-1060.
5. Villalta D, Bizzaro N, Corazza D, Tozzoli R, Tonutti E. Evaluation of a new automated enzyme fluoroimmunoassay using recombinant plasmid dsDNA for the detection of anti-dsDNA antibodies in SLE. J Clin Lab Anal 2002; 16: 227-232.
6. Lopez-Hoyos M, Ayerbe I, Martinez-Taboada VM et al. Clinical utility of antibodies to double-stranded DNA by a new immunofluorescence test. Lupus 2004; 13: 144-147.
7. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on prognosis studies in SLE. Deviation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
10. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
11. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
12. Chen CY, Tseng HM, Chen LC et al. Use of a new fluorescence immunoassay to detect anti-dsDNA antibodies is more correlated with disease activity and complement than the ELISA method in SLE patients. Lupus 2003; 12: 266-273.
13. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991; 34: 937-944.
14. Zonana-Nacach A, Salas M, Sanchez ML, Camargo-Coronel A, Bravo-Gatica C, Mintz G. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol 1995; 22: 45-49.
15. Xie C, Liang Z, Chang S, Mohan C. Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum 2003; 48: 2343-2352.
16. Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCgamma receptor type UA alleles. Arthritis Rheum 2003; 48: 460-470.
17. Kramers C, Hylkema MN, van Bruggen MC et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994; 94: 568-577.